Seres Therapeutics (MCRB) Tops Q1 EPS by 3c

Seres Therapeutics (NASDAQ: MCRB) reported Q1 EPS of ($0.63), $0.03 better than the analyst estimate of ($0.66). Revenue for the quarter came in at $3.02 million versus the consensus estimate of $2.3 million.

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.

You May Also Be Interested In

• Helen of Troy (HELE) Tops Q1 EPS by 22c, Beats on Revenue; Offers FY Guidance
• Penguin Solutions (PENG) Tops Q2 EPS by 28c, Beats on Revenue; Offers FY26 EPS Guidance
• Kura Sushi (KRUS) Tops Q3 EPS by 3c; offers outlook